

2. (Amended) A method according to claim 1, wherein the transduced multi-
potential hematopoietic stem cells are maintained under conditions such that at least
about 92 to 99% of the cells in the G0 phase remain in the G0 phase for at least about
two days.

7. (Amended) A method according to claim 2, wherein the conditions under which
the multi-potential hematopoietic stem cells are maintained include cytokine levels no
greater than about 15 ng/ml IL-3, 15 ng/ml IL-6 and 1.5 ng/ml granulocyte-macrophage
colony stimulating factor.

13. (Amended) A method according to claim 1, wherein the transferred gene
remains integrated into the genome of the multi-potential hematopoietic stem cells for at
least 8 weeks.

19. (Amended) A method according to claim 1, wherein the adeno-associated
virus vector is vCWRHIVAPAP.

20. (Amended) A method according to claim 1, wherein the adeno-associated
virus vector is vCWRHIVASVN.

21. (Amended) A method according to claim 1, wherein the adeno-associated
virus vector is vCWRAP.